Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:26:06 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Oncopeptides Q1 2025 - Strong Q/Q Growth with Japan the Next Catalyst

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Oncopeptides Q1 2025 - Strong Q/Q Growth with Japan the Next Catalyst

2025-05-21 11:02:00

Redey comments on Oncopeptides’ first quarter report 2025. The growth quarter on quarter was 34%, despite a 5% FX headwind. Discussions about a potential deal in Japan are still ongoing. We believe the sales growth trend is stabilising with growing uptake from new markets.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/